WFG Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

WFG Advisors’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-127	Closed	-$3K	–	1738
2017 Q1	$3K	Hold	127	–	–	﹤0.01%	1315
2016 Q4	$4K	Buy	+127	New	+$5.42K	﹤0.01%	1336

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

WFG Advisors's MACK Position: Q2 2017 in Review

WFG Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2017, closing a stake of 127 shares — an estimated $3K sold.

WFG Advisors first reported a position in MACK in Q4 2016 and held it in 2 quarters. The position peaked at $4K in Q4 2016. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

WFG Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
WFG Advisors sold 127 Merrimack Pharmaceuticals, Inc. shares in Q2 2017, an estimated $3K.
WFG Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
WFG Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $4K in Q4 2016.
119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.